Innova Captab profit and loss

Latest FY26

Revenue: ₹1,630cr+31.1% on FY25
EBITDA: ₹243cr+30.5% on FY25
Net profit: ₹143cr+11.6% on FY25
EPS: ₹25.02+11.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

Expenses
	1,749	1,630	1,244	1,081
	9.4	7.4	12.0	12.5
	1,759	1,637	1,256	1,094
	1,084	1,005	800	696
	65.7	58.3	39.2	35.5
	−13.7	−11.0	−24.9	−3.3
	173	167	117	90.7
	18.5	16.9	2.4	21.5
	45.8	45.2	24.8	16.0
	181	167	127	108
	1,554	1,449	1,085	964
	259	243	186	154
	214	198	161	138
Profit
	205	188	171	130
	205	188	171	130
	30.3	25.6	26.8	29.3
	18.0	19.5	16.0	5.9
	48.3	45.1	42.8	35.2
	156	143	128	94.3
	156	143	128	94.3
	0.6	0.4	0.3	1.9
	157	144	129	96.2
	—	—	128	—
Per share
	₹27.31	₹25.02	₹22.41	₹18.66
	₹27.31	₹25.02	₹22.41	₹18.66
Other comprehensive income — detail
	0.6	0.4	0.3	—
	0.6	0.4	0.4	—
	0.0	0.0	0.1	—
	—	—	—	−1.9
	—	143	128	—
Per share — as-filed variants
	₹27.31	₹25.02	₹22.41	₹18.66
	₹27.31	₹25.02	₹22.41	₹18.66
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	613	577	430	353
	35.1%	35.4%	34.5%	32.6%
Adjusted (ex-exceptional items) — derived
	205	188	171	130
	156	143	128	94.3
	₹27.31	₹25.02	₹22.41	₹18.66

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INNOVACAP₹1,049.70

Innova Captab Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMOREPENLAB IOLCP FDC SENORES SANOFI ORCHPHARMA GUJTHEM RPGLIFEMcap ₹6,007 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,081.3	1,243.7	1,630.0	1,749.3
Other Income	12.5	12.0	7.4	9.4
Total Income	1,093.8	1,255.7	1,637.4	1,758.7
Expenses
+ Cost of Materials Consumed	696.1	799.8	1,005.5	1,084.0
+ Purchases of Stock-in-Trade	35.5	39.2	58.3	65.7
+ Changes in Inventories	-3.3	-24.9	-11.0	-13.7
+ Employee Benefit Expense	90.7	116.8	167.2	172.9
+ Finance Costs	21.5	2.4	16.9	18.5
+ Depreciation & Amortisation	16.0	24.8	45.2	45.8
+ Other Expenses	107.8	126.6	167.1	181.0
Total Expenses	964.3	1,084.7	1,449.2	1,554.2
EBITDA	154.5	186.2	242.9	259.5
EBIT	138.5	161.4	197.7	213.6
Profit
PBT before Exceptional Items	129.5	171.0	188.3	204.6
Pretax Income	129.5	171.0	188.3	204.6
+ Current Tax	29.3	26.8	25.6	30.3
+ Deferred Tax	5.9	16.0	19.5	18.0
Tax Expense	35.2	42.8	45.1	48.3
Net Income	94.3	128.3	143.2	156.3
+ Net Income — Continuing Ops	94.3	128.3	143.2	156.3
+ Other Comprehensive Income	1.9	0.3	0.4	0.6
Total Comprehensive Income	96.2	128.5	143.6	156.9
Net Income to Common	—	128.3	—	—
Per Share
Basic EPS	18.66	22.41	25.02	27.31
Diluted EPS	18.66	22.41	25.02	27.31
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	0.3	0.4	0.6
+ Items NOT to be Reclassified to P&L	—	0.4	0.4	0.6
+ Tax on Items NOT to be Reclassified	—	0.1	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-1.9	—	—	—
Comprehensive Income — Owners of Parent	—	128.3	143.2	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	18.66	22.41	25.02	27.31
Diluted EPS — Continuing Operations	18.66	22.41	25.02	27.31
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	353.0	429.6	577.2	613.4
Gross Margin %	32.64	34.54	35.41	35.06
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	129.5	171.0	188.3	204.6
Net Income Adj (tax-effected)	94.3	128.3	143.2	156.3
EPS Adj	18.66	22.41	25.02	27.31
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00
Paid Up Equity Capital	57.2	57.2	57.2	57.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.